Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC
Status:
Recruiting
Trial end date:
2021-03-10
Target enrollment:
Participant gender:
Summary
This study is conducted to explore the safety and efficacy of anlotinib, a tyrosine kinase
inhibitors of vascular endothelial growth factor receptor 2（VEGFR）、FGFR（fibroblast growth
factor receptor）, platelet-derived growth factor receptor（PDGFR） and tumor cell proliferation
related kinase c-Kit, combined with platinum plus pemetrexed in T790M mutation negative
metastatic non-squamous non-small cell lung cancer(NSCLC) after the failure of EGFR-TKI.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sichuan Cancer Hospital and Research Institute
Collaborators:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. CHIATAI TIANQING PHARMACEUTICAL Co.,Ltd